Another drug maker is recalling a medication used to treat high blood pressure and heart failure over concerns that tablets could be contaminated with a cancer-causing agent.

Drug maker Aurobindo Pharma USA is voluntarily recalling 80 lots Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP

The U.S. Food and Drug Administration reported that traces of N-nitrosodimethylamine (NDMA), a “probable human carcinogen,” was found in the active ingredient valsartan in the recalled products.

The recalled medications were distributed nationwide. The New Jersey-based company has not received any reports of adverse effects related to the drugs as of Dec. 31, 2018, when the recall was announced, the FDA said.

A full list of the recalled products is available here. Products can be identified by checking the product name, manufacturer details, and batch or lot number on the bottles. Expiration dates range from May 2019 to March 2021.

Valsartan tablets are used to control high blood pressure and for treatment of heart failure. The FDA says patients who are prescribed

Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP should continue taking their medication, “as the risk of harm to the patient’s health may be higher if the treatment is stopped immediately without any alternative treatment.”

If a patient’s medicine is included in the recall, they should contact their health care professional to discuss alternative treatment options before returning their medication.

Consumers can contact the company at 1-866-850-2876 or by email at: [email protected].

(AP)